世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い



世界のギランバレー症候群治療市場 2019-2023年

Global Guillain-Barr? Syndrome Treatment Market 2019-2023

IRTNTR30224

 

出版社 出版日電子媒体価格ページ数
TechNavio
テクナビオ
2018年11月 US$ 2,500
シングルユーザライセンス
111p

サマリー

この調査レポートは世界のギランバレー症候群治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

109 pages, November 2018

About this market


The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barre syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barre syndrome. Technavio’s analysts have predicted that the Guillain-Barre syndrome treatment market will register a CAGR of more than 5% by 2023.

Market Overview


Recent approvals of immunoglobulins
Immunoglobulins are the first line treatment of Guillain-Barre syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barre syndrome treatment market during the forecast period.
Availability of alternate therapies
Currently there is no cure for Guillain-Barre syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barre syndrome.
For the detailed list of factors that will drive and challenge the growth of the Guillain-Barre syndrome treatment market during the 2019-2023, view our report.

Competitive Landscape


The market appears to be fragmented and with the presence of several companies including CSL and Grifols the competitive environment is quite intense. Factors such as the recent approvals of immunoglobulins and strategic alliances, will provide considerable growth opportunities to Guillain-Barre syndrome treatment manufactures. CSL, Grifols, Octapharma, Shire, and Kedrion are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. The market will witness the emergence of many international and regional GBS treatment companies who offer therapeutics such as immunoglobulins and other therapeutics. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barre syndrome, which is expected to enhance the R&D activities of new drugs for the management of GB syndrome.’



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Immunoglobulins - Market size and forecast 2018-2023
- Other therapeutics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- CSL
- Grifols
- Kedrion
- Octapharma
- Shire
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO




?
Exhibit 01: Global neurological disorder drugs market
Exhibit 02: Segments of global neurological disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Immunoglobulins - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Immunoglobulins - Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: CSL - Vendor overview
Exhibit 45: CSL - Business segments
Exhibit 46: CSL - Organizational developments
Exhibit 47: CSL - Geographic focus
Exhibit 48: CSL - Segment focus
Exhibit 49: CSL - Key offerings
Exhibit 50: CSL - Key customers
Exhibit 51: Grifols - Vendor overview
Exhibit 52: Grifols - Business segments
Exhibit 53: Grifols - Organizational developments
Exhibit 54: Grifols - Geographic focus
Exhibit 55: Grifols - Segment focus
Exhibit 56: Grifols - Key offerings
Exhibit 57: Grifols - Key customers
Exhibit 58: Kedrion - Vendor overview
Exhibit 59: Kedrion - Business segments
Exhibit 60: Kedrion - Organizational developments
Exhibit 61: Kedrion - Geographic focus
Exhibit 62: Kedrion - Segment focus
Exhibit 63: Kedrion - Key offerings
Exhibit 64: Kedrion - Key customers
Exhibit 65: Octapharma - Vendor overview
Exhibit 66: Octapharma - Organizational developments
Exhibit 67: Octapharma - Key offerings
Exhibit 68: Octapharma - Key customers
Exhibit 69: Shire - Vendor overview
Exhibit 70: Shire - Business segments
Exhibit 71: Shire - Organizational developments
Exhibit 72: Shire - Geographic focus
Exhibit 73: Shire - Key offerings
Exhibit 74: Shire - Key customers

?
?

 

COPYRIGHT(C) 2011-2019 DATA RESOURCES, Inc. ALL RIGHTS RESERVED.